Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

Published Date: 09 Mar 2026

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

Read Full News

Latest News

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Todays Updates

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Todays Updates

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Latest News

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

News All Time

Lilly Launches Employer-connect Platform to Broaden Weight-loss Drug Access

Eli Lilly said on Thursday it has rolled out a platform to help employers connect ⁠with organizations offering low-cost benefits and comprehensive obesity-care programs,...

Pharmacist-Led Model Lowers Treatment-Related Hypoglycemia

A collaborative intervention model involving a clinical pharmacist significantly reduces severe hypoglycemia risk without compromising glycemic control.

Bariatric Surgery Rates Fall as GLP-1s Gain Popularity

The use of GLP 1s increased dramatically from 2018 to 2025 among patients eligible for metabolic and bariatric surgery in the US, whereas surgery rates declined notably.

‘Generation GLP-1’ Drives GLP-1-Friendly Food Marketing

Experts warn the label is ‘more marketing than medical’; urge following evidence on nutritional recommendations for GLP-1 therapy.

Lobectomy: Viable Alternative in Medullary Thyroid Carcinoma

Thyroid lobectomy may provide oncologic outcomes similar to those of total thyroidectomy in patients with sporadic medullary thyroid carcinoma, per a meta-analysis of 1371 patients from nine studies.

Vitamin D Deficiency Linked to Dry Eye Disease

Adults with a deficiency of vitamin D are at increased risk for developing dry eye disease than those without low levels of the nutrient, a study finds.

PIP Matches PrEP for Low-Risk HIV

The use of medicine at home offers convenience and curbs costs.

Can Physical Activity Improve Skin Cancer Outcomes?

Physical activity is associated with a reduced risk for all-cause mortality and improved survival in patients with skin cancer, a meta-analysis shows.

Healthy Diet May Cut Cancer Survivors’ Premature Aging Risk

A recent study found reduced premature aging among childhood cancer survivors that adhered to established dietary guidelines.

Alcoholic Chlorhexidine: Better for Catheter Infections?

Skin disinfection with high-concentration chlorhexidine in isopropyl alcohol shows better effectiveness in reducing catheter-related infections.

New Model Predicts In-Hospital Death in Acute Liver Failure

A new machine learning model built using a simple and interpretable approach predicts in-hospital death in patients with acute liver failure and reveals top risk drivers.

Can Nurses Safely Replace Physicians in Some Roles?

An 82-trial Cochrane review finds little difference in mortality, quality of life, or safety when nurses substitute for physicians — but outcomes vary widely by specialty and model.

Less Weight Regain, More Health Loss after Stopping GLP-1s?

Patients on GLP-1s who stop taking the drugs may maintain 25% of their weight loss at one year, but whether their regained weight is mainly fat or lean mass isn’t clear.

Dialysis Patients With Diabetes Face High Amputation Burden

Patients undergoing dialysis, especially those with diabetes as the primary renal disease, face a high risk for lower limb amputation and mortality after amputation, a cohort study finds.

Societies Issue Pharmacologic Obesity Management Guidance

The Obesity Society, Obesity Medicine Association, and the Obesity Action Coalition have published joint guidance incorporating patient input.

Verekitug Improved Chronic Rhinosinusitis With Nasal Polyps

Adverse events were similar between the groups, with more high-grade events occurring in the placebo group.

Recommended News For You

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk

Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?

After two years, a significant left nasal obstruction was finally diagnosed.

Single-dose radiation before surgery can eradicate breast cancer

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

Recommended Articles For You

A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51% 

Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives 

Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy 

Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare in the Mix in President Biden's Farewell Address

2.

Using MRD Status to Deescalate Multiple Myeloma Therapy

3.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

4.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

5.

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

1.

Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control

2.

Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential

3.

Nuclear Medicine's Role in Battling Women's Cancers

4.

Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression

5.

Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

2.

Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

4.

Navigating the Complexities of Ph Negative ALL - Part XVI

5.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot